RANI (Rani Therapeutics Holdings) Quality Rank

View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Rani Therapeutics Holdings Quality Rank Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rani Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

2051 Ringwood Avenue, San Jose, CA, USA, 95131

Website

https://www.ranitherapeutics.com

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.

Executives

Kate Mckinley	officer: CHIEF BUSINESS OFFICER	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Talat Imran	director, officer: CEO	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Cone Investments Limited Partnership	10 percent owner	AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Quiroga Cortes Isidoro Alfonso	10 percent owner	9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Svai S Sanford	officer: CFO	C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen	officer: General Counsel	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim	officer: Chief Scientific Officer	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership	10 percent owner	LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran	director
Andrew Farquharson	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono	director
Lisa Ann Rometty	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131